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Background:  After orthotopic  liver  transplantation  (OLT)  in chronic  hepatitis  B (HBV),  adequate  prophy-
laxis  for  recurrence  of  HBV  in  the  graft  is  mandatory.
Objectives:  Evaluate  safety  of  HBV  prophylaxis  with  tenofovir  and emtricitabine  (TDF/FTC)  after  cessation
of  hepatitis  B immunoglobulin  (HBIG)  after  OLT  in  chronic  HBV.
Study  design:  In 17  consecutive  patients  after  OLT  in  chronic  HBV  we started  TDF/FTC  after  cessation
of  HBIG.  All  had  received  HBIG  >6 months.  15/17  were  HBsAg  negative  and  16/17 had  undetectable
HBV-DNA.
Results:  After  mean  follow-up  of 2 years  16/17  patients  were  alive,  one  died  due to  urosepsis.  All  16  with
undetectable  HBV-DNA  remained  HBV-DNA  negative.  From  15  HBsAg  negative  patients  at  start,  in  one
seroconversion  to positive  HBsAg  occurred,  without  detectable  HBV-DNA.  Liver biochemistry  remained
within  the  normal  ranges.  There  were  no  cases  of  drug  discontinuation.  No  major  side  effects  were
reported.  TDF/FTC  use  saves  D  16,262/year  over  standard-of-care  (HBIG  +  LAM).  This prospective  follow-
up  study  shows  that  in liver  transplantation  for  chronic  hepatitis  B, after  initial  treatment  including  HBIG
for  at  least  6 months  combined  with  or followed  by  (dual)  nucleos(t)ide  analog  therapy,  TDF/FTC  provides
adequate  prophylaxis  against  recurrent  HBV  infection  without  major  side  effects  and  leads  to substantial
cost  savings  over  a regimen  with  HBIG.
Conclusion:  Combined  prophylaxis  with  TDF/ETV  nucleoside  plus  nucleotide  analogs  and  cessation  of
immunoglobulin  after  liver  transplantation  in  chronic  hepatitis  B  is safe  and  effective.Abbreviations: OLT, orthotopic liver transplantation; HBV, hepatitis B virus;
DF/FTC, tenofovir and emtricitabine; HBIG, hepatitis B immunoglobulin; LAM,
amivudine; ADV, adefovir; ETV, entecavir; TDF, tenofovir; FTC, emtricitabine; HIV,
uman immunodeﬁciency virus; HCV, hepatitis C virus; HBsAg, hepatitis B sur-
ace antigen; anti-HBs, hepatitis B surface antibody; HBeAg, hepatitis B e antigen;
nti-HBe, hepatitis B e antibody; HDV, hepatitis delta virus; ALT, alanine amino-
ransferase; AST, aspartate aminotransferase; LAMr, lamivudine resistance; MDRD,
odiﬁcation of diet in renal disease; GFR, glomerular ﬁltration rate; IU, international
nits.
∗ Corresponding author at: Department of Gastroenterology and Hepatology, C4-
,  Leiden University Medical Center, Albinusdreef 2/P.O. Box 9600, 2300 ZC, Leiden,
he  Netherlands. Tel.: +31 71 5263507; fax: +31 71 5248115.
E-mail addresses: B.van Hoek@lumc.nl, bart.van.hoek@inter.nl.net (B. van Hoek).
1 Both authors contributed equally.
386-6532/$ – see front matter ©  2013 Elsevier B.V. All rights reserved.
ttp://dx.doi.org/10.1016/j.jcv.2013.06.035© 2013 Elsevier B.V. All rights reserved.
1. Background
Hepatitis B virus (HBV) related end-stage liver disease has
evolved from a contraindication for orthotopic liver transplantation
(OLT) to an indication with one of the leading graft survival rates
[1,2]. Effective prophylaxis for HBV is vital [3]. With initially 80%
HBV-recurrence after OLT [4,5], long-term intravenous hepatitis B
immunoglobuline (HBIG) reduced this to 36%, and in combination
with lamivudine (LAM) HBV-recurrence fell to 0–11% with 88–100%
long-term patient survival [6–9]. Until recently HBIG + LAM was the
standard of care after OLT with chronic HBV [10,11]. Limited data
show that the combination of telbivudine and HBIG may  also be fea-
sible [12]. However, drug-resistance, high costs and hospitalization
for HBIG-infusion are disadvantages. Intramuscular or subcuta-
neous HBIG abolished the need for admission [13,14]. Recently
successful post-OLT results emerged combining a nucleotide and
nucleoside analog after HBIG-cessation [15–17].
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In chronic HBV, entecavir (ETV) and tenofovir (TDF) induce only
.2% and 0% resistance in over 5 years respectively as compared
o LAM (51–69% at 5 years), ADV (20–29% at 5 years), telbivu-
ine (11–25% at 2 years) and LAM plus ADV (15% at 2 years)
18–24]. Recently, data demonstrated that after OLT prophylaxis
ith ETV without any HBIG could be effective [25], although HBsAg-
ecurrence without HBV-DNA positivity or graft failure in some led
o doubt whether monoprophylaxis with ETV is safe [26]. Since
esistance to TDF did not emerge after six years (AASLD 2012) [27],
DF is a promising alternative for post-OLT HBV prophylaxis, but a
ombination of TDF with emtricitabine (FTC) may  be safer [28].
. Objectives
We  here report the safety of two years of TDF/FTC prophylaxis
nd cessation of HBIG in a cohort of chronic hepatitis B patients
fter liver transplantation.
. Study design
.1. Patients
This was a single center, one arm, open prospective cohort
tudy conducted at the Leiden University Medical Center, Leiden,
he Netherlands, a tertiary referral center for liver disease and
iver transplantation. From 1997 through 2010 286 OLT were per-
ormed in 240 patients. Informed consent was obtained from each
atient, and the study protocol conformed to the ethical guide-
ines of the 1975 Declaration of Helsinki. We  enrolled patients who
eceived OLT for chronic HBV related disease between 1997 and
010 (n = 24). Excluded were those who deceased before the intro-
uction of our new prophylaxis protocols without HBIG (November
009) (n = 5, none had HBV recurrence), patients who  were human
mmunodeﬁciency virus (HIV) positive (n = 0), patients who were
epatitis C (HCV) RNA positive (n = 1) or who had developed cirrho-
is in the liver graft (n = 1). This latter patient had HBV recurrence
hree months after OLT in 1997, after which LAM was  started. The
CV co-infected patient excluded was HBsAg and HBV-DNA and
CV-RNA positive just before OLT, cleared HCV-RNA at the time of
iver transplantation in 1998, was kept on intravenous HBIG and
ne year later had a severe allergic reaction with angio-edema
fter intravenous HBIG, which was stopped then. After that she
emained HBsAg and HBV-DNA negative and is doing well 14 years
fter OLT. Hepatitis delta co-infection (HDV), OLT for hepatocellular
arcinoma or re-transplantation was no reason for exclusion.
Seventeen adult patients (Table 1) were eligible and were
nrolled in our new post-OLT HBV prophylaxis protocol, compris-
ng conversion of current therapy to a combination of TDF and
TC without HBIG. All patients had previously received HBIG for at
east 6 months post transplantation with or without a nucleos(t)ide
nalog.
.2. Hepatitis B prophylaxis
All patients had been administered 10.000 international units
IU) of IV HBIG (Hepatect – Biotest seralc, Zaventem, Belgium) dur-
ng the anhepatic phase, followed by a 4–7 day course of 10.000
nits of IV HBIG (Hepatect) daily. Initially maintenance was with
ntravenous HBIG, which is costly and requires IV admission. When
here was enough evidence on safety and effectiveness, monthly
BIG was given intramuscularly (IM) instead, 1000 IU regardless of
eight and anti-HBs titer, for at least six months. Neither IV nor IM
BIG is ofﬁcially registered in our country for use as prophylaxis
fter OLT. Recently subcutaneous HBIG was registered for use after
LT in Europe, and this less painful and registered medication isical Virology 58 (2013) 67– 73
used since 2011 in the ﬁrst six months after OLT as a weekly self-
administered subcutaneous injection. Before the year 2000 patients
were treated with HBIG monotherapy, from then on a nucleos(t)ide
analog, mostly LAM, was added to the treatment. Since 2006 ﬁfteen
patients had been switched to LAM and ADV without HBIG. In order
to prevent resistance these and the other two patients were con-
verted to a combination of TDF and FTC in the course of 2009 and
2010.
3.3. Surveillance for hepatitis B recurrence
Post OLT patients were seen at least every 3 months with
physical examination and testing on HBsAg, HBV-DNA, routine
hematology and biochemistry including alanine aminotransferase
(ALT), aspartate aminotransferase (AST) and bilirubin, until the last
day of follow-up (up to 36 months): October 29th, 2012. A liver
biopsy was  done 6 months after OLT and when clinically indicated.
HBsAg, HBV-DNA, hepatitis B e antigen (HBeAg), hepatitis B e anti-
body (anti-HBe), hepatitis delta virus antibody (anti-HDV) and HBV
genotype were assessed in pre-OLT samples. Prior to converting
HBV medication to TDF/FTC these tests were repeated. If HBV-DNA
was detectable on qualitative PCR, a quantitative PCR was used to
determine viral load. The primary endpoint of the study was recur-
rence of HBV infection, deﬁned as the reappearance of both HBsAg
and HBV-DNA in serum after its initial disappearance after liver
transplantation. [15] Secondary endpoints were the reappearance
of either HBV-DNA or HBsAg, serum biochemistry, drug side effects
and tolerability, and patient and graft survival. A raise of serum cre-
atinine more than 45 mol/l (0,5 mg/dl) above baseline was deﬁned
as tolerability failure [29].
Qualitative HBsAG, HBeAg and anti-HBe measurements were
carried out using the AxSYM platform (until 2008; Abbott Diagnos-
tics, Abbott Park, IL, USA) and ARCHITECT i2000SR platform (from
2008 onwards; Abbott Diagnostics, Abbott Park, IL, USA) accord-
ing to the manufacturer’s instructions. Qualitative and quantitative
HBV-DNA measurements were performed with the same in-house
developed real-time PCR assay. Primers and probes were designed
using Beacon Designer (Premier Biosoft, Palo Alto, USA) and ampli-
ﬁed an 80 bp PCR fragment from the preS1-S2 region of all HBV
genotypes (protocol available upon request). Sensitivity levels for
qualitative and quantitative measurements are 50–100 copies/ml
and 100–250 copies/ml, respectively. A higher sensitivity of the
qualitative assay has been achieved by using the same real-time
PCR on nucleic acids extracted from a larger volume (1 ml)  of the
clinical sample, by Large Volume Total Nucleic Acid extraction on
the MagNApure (Roche Diagnostics, Almere, The Netherlands). For
quantitative application an external standard curve, calibrated to
commercially available standards, has been used. The assay is sub-
ject to regular proﬁciency testing. Hepatitis D serology and PCR
were determined by the Erasmus Medical Center in Rotterdam, the
Netherlands. HBV genotyping was performed using primers that
ampliﬁed a 653 bp fragment of the S gene. The PCR fragment was
subjected to nucleotide sequencing and BLAST analysis to deter-
mine the genotype.
3.4. Statistical analysis
Data were stored and analyzed using SPSS 17 (SPSS Inc., Chicago,
IL, USA). Analysis on numerical data was done by using a student’s
t-test for paired data, with a signiﬁcance level of 0.05.
4. ResultsBetween November 2009 and August 2010, 17 post OLT patients
were converted from their current HBV prophylaxis to TDF/FTC.
Table 1 depicts their characteristics and medication regimens. Our
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Table 1
Table displays baseline characteristics, HBV status and medication at time of transplantation, medication post transplantation and HBV status at time of conversion to TDF + FTC and at the end of follow-up. Time is reported in
months  post OLT. Pre-OLT is within 24 h before OLT.
Characteristics  Pre-OLT  OLT  Post-OLT  HBV  medication  At start  of  TDF/FTC  At end  of  follow-up
Pt.
No.
M/F  Age  at
start  of
TDF/ETC
HBV
genotype
HDV-
RNA
Anti-
HDV
HBsAg  HBV-
DNA
103copies/ml
HBV-DNA
(Log10
copies/ml
HBV-
DNA)a
HBeAg  Anti-
HBe
Medication  Year  of
OLT
Medication
with
HBIG
(months
post OLT)
On
LAM  + ADV
Without
HBIG
(months
post  OLT)
On
TDF + FTC
without
HBIG
(months
post  OLT)
HBsAg  HBV-
DNA
HBV-
DNA
load
Follow-
up time
(months
on
TDF/FTC)
HBsAg  HBV-
DNA
HBV-
DNA
load
1  M 60 D  pos  pos  pos  1.54(Log3.2)  pos  neg  ADV  2010  -HBIG  +  TDF  +
FTC  0–8
–  8–30  neg  neg  neg  30  neg  U  neg
2 M 25 E  pos  pos  pos  0.1  (Log2.0)  neg  pos  LAM  + ADV  2007  -HBIG  +  LAM  +
ADV 0–6
6–29  29–61  neg  neg  neg  32  neg  neg  neg
3 F 65 D  neg  pos  pos  1400  (Log 6.1)  neg  pos  LAM  2006  -HBIG  +  LAM
0–9
9–49  49–72  U neg  neg  23  neg  neg  neg
4a M 79 A  neg  pos  pos  2.32(Log3.4)  neg  pos  none  1998  -HBIG  0–31
-HBIG +  LAM
31–101
101–140  140–144  neg  neg  neg  4 neg  neg  neg
5 M 55 A  pos  pos  pos  77.6(Log4.9)  pos  neg  ETV  2008  -HBIG  +  LAM  +
ADV 0–6
6–21  21–43  pos neg  U  22  pos neg  neg
6 M 57 A  pos  pos  pos  27000(Log7.4)  neg  pos  none  2005  -HBIG  +  LAM
0–10
10–48  48–71  neg  neg  U  23  neg  neg  U
7 M 60 D  pos  pos  pos  14.7(Log4.2)  neg  pos  none  2001  -HBIG  +  LAM
0–60
60–99  99–134  neg  neg  neg  35  neg  neg  neg
8 M 46 A  neg  pos  neg  neg  neg  pos  none  2006  -HBIG  +  LAM
0–6
6–44  44–72  neg  neg  neg  27  neg  neg  U
9 M 51 –  pos  neg  neg  neg  neg  pos  HBIG  +  LAM
+ ADV b
2009  -HBIG  +  LAM  +
ADV 0–6
6–6  6–36  neg  neg  neg  30  neg  neg  neg
10 M 61 A  neg  pos  pos
< 0.2  (<Log2.3)
neg  pos  LAM  2003  -HBIG  +  LAM
0–44
44–84  84–108  neg  neg  neg  24  neg  neg  neg
11 M 60 A  pos  pos  pos  neg  neg  pos  LAM  2007  -HBIG  +  LAM  +
ADV 0–6
6–32  32–60  neg  neg  neg  28  neg  U  neg
12 M 47 –  neg  pos  pos  0.07(Log1.8)  neg  pos  ADV  2006  -HBIG  +  LAM  +
ADV 0–6
6–44  44–72  neg  neg  neg  27  neg  neg  U
13 M 52 –  neg  border-
line
pos  pos  0.29  (Log  2.5)  neg  pos  LAM  + ADV 2007  -HBIG  +  LAM  +
ADV 0–6
6–33  33–66  neg  neg  neg  33  neg  neg  U
14 M 52 A  neg  pos  pos  0.09(Log2.0)  U  U  LAM  2000  -HBIG  +  LAM
0–118
– 118–142  neg  neg  neg  24  pos neg  neg
15 M 58 A  neg  pos  pos  20.8  (Log  4.3)  neg  pos  none  2002  -HBIG  +  LAM
0–59
59–97  97–121  neg  neg  neg  24  neg  neg  U
16 M 37 A  neg  pos  pos  35610  (Log7.6)  neg  pos  none  2002  -HBIG  +  LAM
0–45
45–84  84–112  neg  neg  neg  29  neg  neg  U
17c M 71 C  neg  pos  pos  8553  (Log6.9)  U  U  none  1998  -HBIG  0–26
-HBIG +  LAM
26–32
LAM 32–72
LAM + ADV:
72–74
LAM  + TDF:
74–132
132–168  pos pos  neg  36  pos neg  neg
M, male; F, female. U, unknown.
a Patient 4 deceased 4 months after conversion to TDF + FTC from urosepsis.
b Patient 9 underwent OLT 6 months before being re-transplanted and was treated as depicted above for 6 months pre-reOLT. Before ﬁrst OLT no HBV treatment was given.
c Patient 17 was re-transplanted after 3 days and became HBsAg positive under HBIG at 26 months post OLT.
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ohort consisted of 1 female and 16 males with a mean age of 55
ears (Standard deviation (SD) 12, range 25–79 years). Two  patients
eceived a second liver transplantation, the ﬁrst patient (no. 17) was
e-transplanted after 3 days because of primary non-function, and
he other patient was re-transplanted after 6 months because of
on-anastomotic biliary strictures (no. 9). Mean time after trans-
lantation at time of conversion to TDF/FTC was 62 months (SD
3, range 0.3–140 months), and 15 out of 17 (88%) were then at
east one year post transplantation. Mean follow-up after medi-
ation conversion to TDF/FTC was 26 months (SD 7, range 4–36
onths).
HBV genotype could be determined in 14 of 17 patients. HDV co-
nfection was present in 7 of 17 patients (41%). All but one patient
ere HBsAg positive at the time of transplantation and HBV-DNA
as detectable in 15 of 17 patients. In 14 patients DNA-load could
e quantiﬁed, as depicted in Table 1. HBeAg and anti-HBe status
rior to transplantation was available for all but two patients. Two
atients were HBeAg positive and anti-HBe negative, the other 13
ere HBeAg negative and anti-HBe positive. Prior to transplanta-
ion 10 of 17 patients were on (dual) nucleos(t)ide therapy. After
ransplantation all patients received HBIG for at least 6 months
range 6–118 months), mostly combined with (dual) nucleos(t)ide
herapy. Fifteen patients had been converted to LAM/ADV without
BIG before the switch to TDF/FTC. At time of medication conver-
ion 2 of the 17 patients were HBsAg positive and 1 of them was
ound positive with HBV-DNA on qualitative PCR.
ig. 1. Patient 14. Anti-HBs in IU/L. HBsAg in sample relative luminescence units/ control
ycle  threshold. HBV-DNA quantitative in copies per mL.  OLT, orthotopic liver transplantatical Virology 58 (2013) 67– 73
At the end of this study (October 2012) 16 out of 17 patients
(94%) were alive, one patient had died due to urosepsis, unrelated
to study medication and with a functioning graft without signs of
HBV recurrence (duration of follow-up: 4 months). There were no
cases of graft loss and or graft failure.
No HBV recurrence (both HBsAG and HBV-DNA positivity)
occurred in the 16 patients at risk. In one (6,7%) of the 15 patients
who were HBsAg negative at time of conversion to TDF/FTC, sero-
conversion from negative to positive HBsAg occurred 13 months
after therapy switch and HBsAg persisted until the end of follow-
up at 24 months. HBV-DNA was  detectable once, three months
after therapy switch (when HBsAg was still negative). This patient
(number 14 in Table 1, Fig. 1) was  a 52 year-old male, trans-
planted in the year 2000 being HBsAg and HBV-DNA positive. He
received HBIG and LAM for 10 years (118 months) before treatment
switch to TDF/FTC. Being on HBIG and LAM, HBsAg measurements
had been negative, but HBV-DNA was detected twice in very low
amounts (<200 copies/ml), one and ﬁve years after transplanta-
tion. Liver biochemistry remained within the normal ranges and
aminotransferases did not signiﬁcantly change after conversion
to TDF/FTC. There were reasons to doubt compliance to medica-
tion. The other 15 patients with undetectable HBV-DNA at time of
treatment conversion remained negative for HBV-DNA during the
complete follow-up time.
One patient (no. 17) was HBsAg positive and had detectable
HBV-DNA below the limit for quantiﬁcation at time of conversion.
 relative luminescence units, <1 non-reactive, ≥1 reactive. HBV-DNA qualitative in
ion; Pos, positiv; Neg, negative.
D.J.W. Wesdorp et al. / Journal of Clinical Virology 58 (2013) 67– 73 71
Table 2
Table displays chemistry and hematology tests at time of conversion to study medication and at the end of follow up. Mean values are displayed as absolute numbers with
standard deviation.
Baseline mean (SD) At end of follow-up mean (SD) Paired t-test mean difference p-value
Creatinine (mol/L) 117 (41) 115 (42) −2.2 0.589
MDRD GFR (mL/min/1,73 m2) 67 (26) 67 (24) 0.3 0.927
AST  (U/L) 23 (6) 23 (7) 0.06 0.971
ALT  (U/L) 26 (26) 22 (10) −3.5 0.500
Bilirubine (mol/L) 17 (10) 14 (6) −2.8 0.118
Sodium (mmol/L) 140 (2) 143 (3) 2.3 0.004
Glucose (mmol/L) 6.0 (1.8) 6.1 (2.8) 0.1 0.777
WBC  count (*109 L–1) 5.8 (1.8) 6.1 (1.8) 0.2 0.421
MDRD, modiﬁcation of diet in renal disease; GFR, glomerular ﬁltration rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; WBC, white blood cell count.
Table  3
Cost in Euro’s for HBV prophylaxis post OLT in chronic hepatitis B in 2012 in the Netherlands.
Medication D Cost per dose D Yearly cost
Subcutaneous 1000 IU HBIG, >75 kg Weekly 427,96 22254,06
Subcutaneous 500 IU HBIG, <75 kg Weekly 213,98 11127,03
Lamivudine 100 mg  Daily 272 1058,06
Adefovir dipivoxil 10 mg Daily 1489 5823,89
Subcutaneous 1000 IU HBIG & Lamivudine 100 mg  23312,12
Subcutaneous 500 IU HBIG & Lamivudine 100 mg 12185,09
Lamivudine 100 mg  & Adefovir 10 mg  Daily 1761 6881,95
Tenofovir 245 mg  & Emtricitabine 200 mg Daily 1802 7049,59
Tenofovir 245 mg  Daily 1184 4632,24
ily 159
T amivu
T
i
a
p
h
G
s
i
a
s
c
s
a
G
w
u
s
t
s
u
a
T
c
N
m
c
s
a
T
i
w
5
w
iEntecavir 1 mg  Da
enofovir and emtricitabine use saves D 16262/year over standard-of-care (HBIG + l
his was a case of previous HBV recurrence and HBV-DNA remained
ntermittently detectable by qualitative but not the quantitative
ssay during follow-up.
Renal function remained stable during follow-up for most
atients (Table 2) and no tolerability failure occurred. Ten patients
ad a change in Modiﬁcation of Diet in Renal Disease (MDRD) based
lomerular Filtration Rate (GFR) of ≤5 mL/min/1.73m2 between
tart and end of follow-up. Three patients showed a decrease
n MDRD GFR (range decrease: 9–41 mL/min/1.73m2), and four
n increase (range: 7–18 mL/min/1.73m2). At the time of therapy
witch eight patients had a MDRD GFR of <60 mL/min/1.73m2, as
ompared to four at the end of follow-up (no new cases). Patient 1
howed a serum creatinine rise of 37 mol/L from the time of ther-
py switch to the last day of follow-up, with a decrease of MDRD
FR from 106 mL/min/1.73m2 to 65 mL/min/1.73m2. Although this
as a clinically signiﬁcant rise, the criterion for tolerability fail-
re was not met. Phosphate levels were not tested after therapy
witch, but 24 h urine analysis showed no evidence of proximal
ubular dysfunction. The decreased kidney function may  also be a
ide effect of tacrolimus use. There were no cases of drug discontin-
ation. No signiﬁcant changes were found in routine hematology
nd routine chemistry lab results before versus after change to
DF/FTC (Table 2), with one exception: sodium levels were signiﬁ-
antly higher (mean difference 2.3 mmol/L) after switch to TDF/FTC.
o major side effects have been reported during the routine 3-
onthly examinations. One patient reported constipation after the
onversion to TDF/FTC; another patient reported transpiration and
leeping problems. A calculation of the cost of HBV prophylaxis
fter OLT with chronic HBV shows substantial cost savings for the
DF/FTC regimen over a HBIG-containing regimen (yearly cost sav-
ngs of D 16262 compared to the current standard-of-care of HBIG
ith LAM) (Table 3).
. DiscussionOur ﬁndings indicate that cessation of HBIG and prophylaxis
ith TDF/FTC provides an adequate defense against recurrent HBV
nfection after OLT. We  found no recurrence of HBV infection,7 6249,48
dine). IU, international units.
as deﬁned by both a positive HBsAg and HBV-DNA, on TDF/FTC.
One HBsAg negative patient became HBsAg positive, with unde-
tectable HBV-DNA, and ALT within the normal range; the long-term
consequences of this HBsAg conversion without HBV-DNA posi-
tivity are as yet unknown. The percentage of HBsAg recurrence
under TDF/FTC we describe (1/15, 6.7%) is in concordance with
comparable series with HBIG cessation, with recurrence rates of
3.3–6.7% [15,17]. There was  no signiﬁcant rise in serum creati-
nine or tolerability failure for TDF/FTC. The slight rise in sodium
levels was not clinically signiﬁcant, in contrast to a recent study
where a serum creatinine increase and tolerability failure occurred
in 5.6% of patients using either TDF or TDF/FTC [29]. However, this
was in patients with decompensated cirrhosis. The recently pub-
lished other study with TDF/FTC after OLT had 3/21 patients in
whom HBsAg became positive; two cleared HBsAg later, a non-
compliant patient temporarily developed HBV-DNA positivity; in
that study 4/21 patients developed acute renal failure [28]. It there-
fore remains important to carefully conduct follow-up in patients
with dual oral antiviral therapy, especially in those taking other
nephrotoxic medication like calcineurin inhibitors or with chronic
renal impairment.
Data on combining a nucleotide and nucleoside analog for HBV
prophylaxis after OLT are limited. A recent study with nucleo-
side/nucleotide combination therapy after OLT, treating 61 patients
with various regimes, reports a 2.3% recurrence rate of HBsAg with-
out detectable HBV-DNA or liver biochemistry abnormalities [17].
The patients who became HBsAg positive were on a regimen of
LAM + TDF. Angus et al. found HBsAg recurrence without detectable
HBV-DNA in 1 out of 15 patients treated with ADV + LAM after ini-
tial treatment with HBIG and LAM for at least 12 months [17]. A
recent abstract on 37 patients randomized to TDF/FTC with or with-
out HBIG showed no HBsAg recurrence or detectable HBV-DNA in
either group with maximum follow-up of 96 weeks and no signiﬁ-
cant changes in liver or kidney function [30].At 5 years lamivudine resistance (LAMr) has been observed
in 65–69% of naïve patients and genotypic resistance to ADV in
20–29% [18,19,31]. Combination of LAM and ADV showed 15%
genotypic resistance at 2 years in naïve patients. [19] LAMr based
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[
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n the M204 V/I mutation results in resistance to telbivudine, FTC
nd clevudine, but not to ADV and TDF. Resistance to ADV occurs
n patients with LAMr HBV at a rate of 25% after 2 years [32].
TV susceptibility decreases 8-fold in LAMr [33]. ETV + HBIG was
uperior to LAM + HBIG after OLT [34], while monoprophylaxis
TV was superior to LAM [35]. HBsAg positivity but no HBV-DNA
ositivity or recurrence was seen with ETV or TDF after HBIG dis-
ontinuation [36]. Meta-analysis of ETV and TDF with or without
BIG included 517 OLT-recipients from 17 studies. Patients under
BIG + LAM (6.1% 115/1889) developed HBV recurrence signiﬁ-
antly more often than patients under HBIG with TDF or ETV (1.0%,
/303, p < 0.001), and numerically but not signiﬁcantly more fre-
uently than in TDF or ETV after discontinuation of HBIG (3.9%,
/102), while monoprophylaxis with ETV or TDF was not differ-
nt from HBIG + LAM if the deﬁnition of HBV recurrence was  based
n HBV-DNA detectability (3.8% vs. 0.9%) [37]. This supports use
f prophylaxis including ETV or TDF from OLT on. In the current
tudy TDF and FTC was chosen because FTC might increase the
arrier for development of resistance to TDF in these susceptible
atients [38]. A further advantage is the existence of a combined
DF/FTC preparation. Prophylaxis without HBIG injections saves
ver D 16000/year and abolishes the need for testing anti-hepatitis
 surface-antibody (anti-HBs) titers.
The small number of patients and potential selection bias are the
ain limitations of this study. Also at the time of therapy switch
o TDF/FTC, most patients had been stable on LAM/ADV, indicating
hat this group may  be more prone to a favorable course on TDF/FTC.
atient characteristics at baseline vary regarding time post-OLT and
edication regimes before conversion to TDF/FTC, which was sim-
lar to the other studies. A relatively large percentage is co-infected
ith HDV, which might inﬂuence risk of HBV recurrence. When
rawing conclusions these limitations have to be kept in mind.
arger, multi-center, randomized controlled trials are needed to
urther examine long term effects of the combination of TDF/FTC.
The current two-year prospective follow-up study shows that
essation of HBIG more than six months after OLT in patients with
hronic hepatitis B, using a combination of (LAM/ADV followed by)
DF/FTC, is safe and provides adequate prophylaxis against recur-
ent HBV infection. HBV prophylaxis after OLT shows substantial
ost savings for TDF/FTC over a HBIG-containing regimen. Larger
nd long-term studies with HBIG discontinuation and HBIG-free
BV prophylaxis with nucleos(t)ide analogs with a high genetic
esistance barrier after OLT are warranted.
thical approval
Not required.
ontributions
The study was conceptualized and designed by D.J.W. Wesdorp,
.  Knoester, A.C.T.M. Vossen and B. van Hoek. D.J.W. Wesdorp, M.
noester, E.C.J. Claas and B. van Hoek acquired the data. Analy-
is and interpretation of data were done by D.J.W. Wesdorp, M.
noester and B. van Hoek. The manuscript was also drafted by them.
.J.W. Wesdorp, M.  Knoester, A.E. Braat, M.J. Coenraad, A.C.T.M.
ossen and B. van Hoek revised the article critically for impor-
ant intellectual content. All authors gave the ﬁnal approval of the
ersion to be submitted.onﬂicts of interest
None.
[ical Virology 58 (2013) 67– 73
Acknowledgement
This study was  supported by an unrestricted research grant from
Gilead Sciences; this funder was not involved in any way  with the
study itself. We thank Mrs. Lida Beneken-Kolmer, R.N. for organi-
zational support for this study.
References
[1] Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, Neuhaus
R,  Berg T, Hopf U, Neuhaus P. Increasing applicability of liver transplantation for
patients with hepatitis B-related liver disease. Hepatology 2002;35:1528–35.
[2] Kim WR,  Poterucha JJ, Kremers WK,  Ishitani MB, Dickson ER. Outcome
of  liver transplantation for hepatitis B in the United States. Liver Transpl
2004;10:968–74.
[3] Harrison RF, Davies MH, Goldin RD, Hubscher SG. Recurrent hepatitis B in liver
allografts: a distinctive form of rapidly developing cirrhosis. Histopathology
1993;23:21–8.
[4] Freeman RB, Sanchez H, Lewis WD,  Sherburne B, Dzik WH,  Khettry U, Hing
S,  Zeldis JB, Jenkins RL. Serologic and DNA follow-up data from HBsAg-
positive patients treated with orthotopic liver transplantation. Transplantation
1991;51:793–7.
[5] O’Grady JG, Smith HM,  Davies SE, Daniels HM,  Donaldson PT, Tan KC,
Portmann B, Alexander GJ, Williams R. Hepatitis B virus reinfection after ortho-
topic liver transplantation. Serological and clinical implications. J Hepatol
1992;14:104–11.
[6] Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M,  Benhamou JP, Brechot
C,  Bismuth H. Passive immunoprophylaxis after liver transplantation in HBsAg-
positive patients. Lancet 1991;337:813–5.
[7] Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H.
Liver transplantation in European patients with the hepatitis B surface antigen.
N  Engl J Med  1993;329:1842–7.
[8] Grellier L, Mutimer D, Ahmed M,  Brown D, Burroughs AK, Rolles K, McMaster P,
Beranek P, Kennedy F, Kibbler H, McPhillips P, Elias E, Dusheiko G. Lamivudine
prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis.
Lancet 1996;348:1212–5.
[9] Angus PW,  McCaughan GW,  Gane EJ, Crawford DH, Harley H. Combina-
tion low-dose hepatitis B immune globulin and lamivudine therapy provides
effective prophylaxis against posttransplantation hepatitis B. Liver Transpl
2000;6:429–33.
10] Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl
2004;10:S74–85.
11] EASL clinical practice guidelines. Management of chronic hepatitis B virus infec-
tion.  J Hepatol 2012;57:167–85.
12] Perrella A, Lanza AG, Santaniello W,  Pisaniello D, Dicostanzo G, Calise F, Amato
G, Marcos A, Cuomo O. Telbivudin as prophylaxis for hepatitis B virus recur-
rence after liver transplantation: a case series in single-center experience.
Transplant Proc 2012;44:1986–8.
13] Burbach GJ, Bienzle U, Neuhaus R, Hopf U, Metzger WG,  Pratschke J, Neuhaus P.
Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of
hepatitis B reinfection after orthotopic liver transplantation. Transplantation
1997;63:478–80.
14] Yahyazadeh A, Beckebaum S, Cicinnati V, Klein C, Paul A, Pascher A, Neuhaus R.
Efﬁcacy and safety of subcutaneous human HBV-immunoglobulin (Zutectra) in
liver transplantation: an open, prospective, single-arm phase III study. Transpl
Int 2011;24:441–50.
15] Angus PW,  Patterson SJ, Strasser SI, McCaughan GW,  Gane E. A random-
ized study of adefovir dipivoxil in place of HBIG in combination with
lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology
2008;48:1460–6.
16] Nath DS, Kalis A, Nelson S, Payne WD,  Lake JR, Humar A, Hepatitis B. prophy-
laxis post-liver transplant without maintenance hepatitis B immunoglobulin
therapy. Clin Transplant 2006;20:206–10.
17] Saab S, Desai S, Tsaoi D, Durazo F, Han S, McClune A, Holt C, Farmer D, Goldstein
L,  Busuttil RW.  Posttransplantation hepatitis B prophylaxis with combination
oral nucleoside and nucleotide analog therapy. Am J Transplant 2011;11:511–7.
18] Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G,  Rizzetto M,
Marcellin P, Lim SG, Goodman Z, Ma  J, Brosgart CL, Borroto-Esoda K, Arter-
burn S, Chuck SL. Long-term therapy with adefovir dipivoxil for HBeAg-negative
chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743–51.
19] Sung JJ, Lai JY, Zeuzem S, Chow WC,  Heathcote EJ, Perrillo RP, Brosgart CL,
Woessner MA, Scott SA, Gray DF, Gardner SD. Lamivudine compared with
lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic
hepatitis B. J Hepatol 2008;48:728–35.
20] Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski
MJ,  Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis
B  virus resistance to entecavir in nucleoside-naive patients is rare through 5
years of therapy. Hepatology 2009;49:1503–14.21] Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H, Wan
M,  Chen C, Wu S, Chen Y, Xu J, Wang Q, Wei  L, Chao G, Constance BF, Harb G,
Brown NA, Jia J. Telbivudine versus lamivudine in Chinese patients with chronic
hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology
2008;47:447–54.
of Clin
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[D.J.W. Wesdorp et al. / Journal 
22] Lai CL, Leung N, Teo EK, Tong M,  Wong F, Hann HW,  Han S, Poynard T, Myers M,
Chao G, Lloyd D, Brown NA. A 1-year trial of telbivudine, lamivudine, and the
combination in patients with hepatitis B e antigen-positive chronic hepatitis B.
Gastroenterology 2005;129:528–36.
23] Lai CL, Gane E, Liaw YF, Hsu CW,  Thongsawat S, Wang Y, Chen Y, Heathcote
EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM,  Zeuzem S, Moon YM,
Goodman Z, Chao G, Constance BF, Brown NA. Telbivudine versus lamivudine
in  patients with chronic hepatitis B. N Engl J Med  2007;357:2576–88.
24] Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns
M,  Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ,  Papatheodor-
idis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV. 2-Year GLOBE trial
results: telbivudine Is superior to lamivudine in patients with chronic hepatitis
B.  Gastroenterology 2009;136:486–95.
25] Fung J, Cheung C, Chan SC, Yuen MF,  Chok KS, Sharr W,  Dai WC,  Chan AC,
Cheung TT, Tsang S, Lam B, Lai CL, Lo CM.  Entecavir monotherapy is effective
in  suppressing hepatitis B virus after liver transplantation. Gastroenterology
2011;141:1212–9.
26] Samuel D, Roche B. Combined prophylaxis might still be better than mono-
prophylaxis with entecavir following liver transplantation for hepatitis B.
Gastroenterology 2012;142:e34–5.
27] Heathcote EJ, Marcellin P, Buti M,  Gane E, de Man  RA, Krastev Z, Germanidis G,
Lee SS, Flisiak R, Kaita K, Manns M,  Kotzev I, Tchernev K, Buggisch P, Weilert F,
Kurdas OO, Shiffman ML,  Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K,
Mondou E, Anderson J, Sorbel J, Rousseau F. Three-year efﬁcacy and safety of
tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenter-
ology 2011;140:132–43.
28] Stravitz RT, Shiffman ML,  Kimmel M,  Puri P, Luketic VA, Sterling RK, Sanyal
AJ, Cotterell AH, Posner MP,  Fisher RA. Substitution of tenofovir/emtricitabine
for  Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver
transplantation. Liver Int 2012;32:1138–45.29] Liaw YF, Sheen IS, Lee CM,  Akarca US, Papatheodoridis GV, Suet-Hing WF,
Chang TT, Horban A, Wang C, Kwan P, Buti M,  Prieto M, Berg T, Kitrinos K,
Peschell K, Mondou E, Frederick D, Rousseau F, Schiff ER. Tenofovir disoproxil
fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompen-
sated chronic hepatitis B liver disease. Hepatology 2011;53:62–72.
[ical Virology 58 (2013) 67– 73 73
30] Teperman L, Spivey JR, Poordad F, Schiano T, Bzowej N, Pungpapong
S. Emtricitabine-tenofovir DF combination ± HBIG post/orthotopic liver
transplantation to prevent hepatitis B recurrence in patients with nor-
mal  to moderate renal impairment: interim results. J Hepatol 2010;52:
S12–3.
31] Marcellin P, Chang TT, Lim SG, Sievert W,  Tong M,  Arterburn S, Borroto-Esoda K,
Frederick D, Rousseau F. Long-term efﬁcacy and safety of adefovir dipivoxil for
the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology
2008;48:750–8.
32] Yeon JE, Yoo W,  Hong SP, Chang YJ, Yu SK, Kim JH, Seo YS, Chung HJ, Moon
MS,  Kim SO, Byun KS, Lee CH. Resistance to adefovir dipivoxil in lamivu-
dine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut
2006;55:1488–95.
33] Baldick CJ, Eggers BJ, Fang J, Levine SM,  Pokornowski KA, Rose RE, Yu CF, Ten-
ney DJ, Colonno RJ. Hepatitis B virus quasispecies susceptibility to entecavir
conﬁrms the relationship between genotypic resistance and patient virologic
response. J Hepatol 2008;48:895–902.
34] Ueda Y, Marusawa H, Kaido T, Ogura Y, Ogawa K, Yoshizawa A, Hata K,
Fujimoto Y, Nishijima N, Chiba T, Uemoto S. Efﬁcacy and safety of prophy-
laxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis
B  recurrence after living-donor liver transplantation. Hepatol Res 2013;43:
67–71.
35] Cai CJ, Lu MQ,  Chen YH, Zhao H, Li MR,  Chen GH. Clinical study on prevention
of HBV re-infection by entecavir after liver transplantation. Clin Transplant
2012;26:208–15.
36] Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis
E.  Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide
analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis
2012;14:479–87.
37] Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide
analogue(s) for prophylaxis from hepatitis B Virus recurrence after
liver transplantation: a systematic review. Am J Transplant 2013;13:
353–62.
38] Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues.
Gastroenterology 2009;137:1593–608.
